CN105274185A - Sputum treating liquid for detecting Mycobacterium tuberculosis - Google Patents
Sputum treating liquid for detecting Mycobacterium tuberculosis Download PDFInfo
- Publication number
- CN105274185A CN105274185A CN201510784562.4A CN201510784562A CN105274185A CN 105274185 A CN105274185 A CN 105274185A CN 201510784562 A CN201510784562 A CN 201510784562A CN 105274185 A CN105274185 A CN 105274185A
- Authority
- CN
- China
- Prior art keywords
- sputum
- treatment solution
- tuberculosis
- treating liquid
- tubercule bacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010036790 Productive cough Diseases 0.000 title claims abstract description 54
- 210000003802 sputum Anatomy 0.000 title claims abstract description 54
- 208000024794 sputum Diseases 0.000 title claims abstract description 54
- 239000007788 liquid Substances 0.000 title abstract description 8
- 241000187479 Mycobacterium tuberculosis Species 0.000 title abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004327 boric acid Substances 0.000 claims abstract description 3
- 239000012153 distilled water Substances 0.000 claims abstract description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 17
- 238000005336 cracking Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 229940066491 mucolytics Drugs 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 abstract description 13
- 238000001514 detection method Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 210000003097 mucus Anatomy 0.000 abstract description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 3
- 238000003759 clinical diagnosis Methods 0.000 abstract description 3
- 238000011835 investigation Methods 0.000 abstract description 3
- 208000026435 phlegm Diseases 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 abstract 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 235000010338 boric acid Nutrition 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000005260 corrosion Methods 0.000 abstract 1
- 230000007797 corrosion Effects 0.000 abstract 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 241000186359 Mycobacterium Species 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 3
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- HZLHRDBTVSZCBS-UVJJDBRNSA-N 4-[(e)-(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline;hydrochloride Chemical compound Cl.C1=CC(=N)C(C)=C\C1=C(C=1C=C(C)C(N)=CC=1)/C1=CC=C(N)C=C1 HZLHRDBTVSZCBS-UVJJDBRNSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A sputum treating liquid for inspecting standard films of Mycobacterium tuberculosis in sputum comprises ethyl alcohol, isopropyl alcohol, boric acid, disodium EDTA, SDS, a mucus dissolving agent and distilled water and is capable of dissolving phlegm, deactivating pathogenic bacteria such as Mycobacterium tuberculosis as well as viruses in sputum, preventing corrosion and splitting exfoliative cells in sputum. Applied with simple centrifugal operation, the sputum treatment with the sputum treating liquid enables 8 to 10 spits of sputum to be treated at a time, and even sputum left for 24 hours, the treatment quantity of sputum is increased, standard operation is achieved through a standard automatic film-making technique, the operation is simple and easy, detection sensitivity is improved, detection is accurate and reliable, and the sputum treating liquid is suitable for the general investigation of tuberculosis high-risk groups, screening of rural tuberculosis and clinical diagnosis of tuberculosis.
Description
Technical field
The present invention relates to a kind of sputum treatment solution detected for tubercule bacillus, for pulmonary tuberculosis high risk population generaI investigation, Pulmonary Tuberculosis in Rural examination and clinical diagnosis of tuberculosis, belong to external diagnosis reagent field.
Background technology
Mycobacterium tuberculosis (M.tuberculosis), is commonly called as tubercule bacillus, is cause pathogenic bacteria lungy.The each organ of whole body can be invaded, but be the most common with pulmonary tuberculosis.Tuberculosis is still important transmissible disease so far.According to WHO, about there are 8,000,000 new cases to occur every year, have at least 3,000,000 people to die from this disease.China is one of 22 tuberculosis states occurred frequently in the whole world, and the tuberculosis patient of West Pacific region 70% is in China.According to Ministry of Health's investigation display, the whole nation about has 5.5 hundred million people to infect tubercule bacillus, existing active tuberculosis patient 4,500,000, wherein has communicable patient 1,500,000, annual newly-increased tuberculosis patient about 1,300,000.The patient of China 80% is distributed in rural area, and the patient of 75% is between twenty and fifty.China dies from number lungy for 1 year and reaches 130,000, suitable with the number dying from traffic accident, occupy first of various disease death reason, living standards of the people improve after the founding of the state, hygienic state is improved, particularly carried out mass prevention and mass treatment, the general bcg vaccination of children, M & M lungy greatly reduces.But it should be noted that some area is in the world because of the application of acquired immune deficiency syndrome (AIDS), drug abuse, immunosuppressor, the reason such as excessive drinking and poverty, sickness rate is on the rise again.Mycobacterium tuberculosis is elongated slightly bending bacillus, size 1 ~ 4 × 0.4 μm.The bacteria cell wall lipid content of Mycobacterium is higher, accounts for 60% of dry weight, particularly has a large amount of mycolic acid (mycolicacid) to be enclosed in the outside of peptidoglycan layer, can affect penetrating of dyestuff.Containing lipid in Mycobacterium cell wall, therefore to alcohol sensible, in 70% ethanol, 2min is dead.In addition, lipid can prevent thalline loss of moist, therefore strong especially to the resistibility of drying.Stick on dust and keep infectivity 8 ~ 10 days, can survive in dry phlegm 6 ~ 8 months.Mycobacterium tuberculosis, to damp and hot sensitivity, heats 62 ~ 63 DEG C in a liquid and within 3 minutes, is namely killed for 15 minutes or 70 DEG C.Mycobacterium tuberculosis is to ultraviolet-sensitive.Direct sun exposure a few hours can be killed, and can be used for the sterilization of tubercular's clothes, books etc.Mycobacterium generally uses neat Buddhist nun (Ziehl-Neelsen) Ziehi-Neelsen stain, heats after dyeing and can catch, but not easily to decolour with 3% acidic alcohol with 5% carbolfuchsin.Redye with methylene blue if add, then mycobacterium takes on a red color again, and the material in other bacteriums and background is blue.The detection of tubercule bacillus is the key reducing M & M lungy with prevention.The method of current detection tubercule bacillus mainly contains etiology method, immunological method and molecular biology method.
Pathogeny detection is tuberculosis diagnosis method unique at present, and etiology method mainly contains two kinds: one, Sputum smears method.This is the most basic bacteriology checking method that tuberculosis laboratory, the whole world is all using, and have fast and convenient and inexpensive etc. advantage, smear methods has following several: 1, Ziehi-Neelsen stain.Classical way, clinically widely uses.2, fluorescent method.With fluorescent microscope, can increase work efficiency.3, dye method is joined.Be combined with fluorescence colour by Ziehi-Neelsen stain.Sputum smears method is the clinical diagnosis method that cheapness is easy fast, but traditional Sputum smears method positive rate is too low.Cannot stdn, the technology of examined person and sense of responsibility impact larger.Two, Sputum culturing method.The advantage of tubercule bacillus general culture method is that sensitivity, specific degree, accuracy are higher, and be that qualification is dead, the reliable method of viable bacteria, being the irreplaceable method of current living stems, is also the main monitoring index of chemotherapy side effect; Shortcoming is that incubation time is long, needs 4-8 week just can report the result, the shell vial method newly gone out, and instrument price is expensive and need inlet liquid substratum, costly, and unfavorable popularization.
Sputum smears detection mode clinical is at present after obtaining sputum sample, get wherein a part of direct smear dyeing microscopic examination, the cell come off because sputum sample viscosity material is many, mobility is bad, containing human body and the tubercule bacillus limited amount that may exist, all bacteriums in sputum cannot effectively be collected on slide by this way.Therefore, if take corresponding way or reagent sputum to be carried out liquefaction processing release tubercule bacillus, simultaneously cracking human body cast-off cells wherein, so just by simple centrifugal treating whole tubercule bacillus can be collected and carry out film-making.Not only increase the bacterium visual field density under microscope, also eliminate the interference of mucus and human body cast-off cells simultaneously, greatly improve diagnostic sensitivity.
Summary of the invention
In order to solve the shortcoming in Sputum smears practical application, contriver, by large quantifier elimination and screening experiment, obtains the sputum prescription for the treatment of liquid of innovation, and this treatment solution has use safety, not containing hazardous chemical; Biological safety is good, pathogenic micro-organism in the process of liquefaction sputum in quick inactivating sample; Collection bacterium is effective, can a large amount of sputum of primary treatment, reaches the object of concentrated bacterium; Easy to operate, the advantages such as normal-temperature operation, normal temperature transport.
Utilize the sputum treatment solution process sputum in this invention, in simple blending process, sputum can be clarified very soon, cause of disease in sputum sample obtains thorough deactivation simultaneously cracking human body cast-off cells wherein and keeps the form of tubercule bacillus complete, and after film-making, the acid-fast stain in the tubercule bacillus that slide adheres to and downstream, fluorescent dye or combined staining operate mates completely.
Embodiment
Specific embodiments of the invention following (preparation 100ml treatment solution):
1. get distilled water 65 milliliters, put into measuring cup, measure boric acid 0.6g, EDETATE SODIUM 0.1g, SDS0.1g respectively, add in measuring cup to stir and fully dissolve for 10 minutes.
2. get dehydrated alcohol 10 milliliters respectively, Virahol 20 milliliters, mucolytic agent 5 milliliters add in measuring cup to stir and be mixed for 5 minutes.
3. step one and step 2 liquid are poured into respectively in beaker to stir and be mixed for 10 minutes.Namely the configuration of sputum treatment solution is complete.
using method
To be spat into by sputum in the pipe that sputum treatment solution is housed or get sputum add in treatment solution from getting phlegm tank, mixing allows treatment solution carry out liquefaction processing to sample, leaves standstill the 1-3 minute that vibrates after 5 minutes, marker samples; Heat sample, put into 70 DEG C of constant temperature water box 10-15 minute, this step can be omitted, because sputum treatment solution is by the tubercule bacillus complete inactivation in sputum, this step is the further guarantee to deactivation; Taking-up sample is put into whizzer directly centrifugal (4000 turns) 5 minutes, remove supernatant, precipitate and suspend for subsequent use with a small amount of pure water.
Actual use shows, after using this treatment solution, remain under mirror without mucus, cast-off cells interference is few, clear background, bacterium visual field density is large, and ne ar is intact, completely eliminated the background interference of mucus, add bacterial density, improve sensitivity, reduce difficulty and the fatigue strength of read tablet person, improve the efficiency of diagnosis.
technical superiority
The present invention has abandoned traditional strong alkali solution or the sputum treatment solution containing toxic starting materials, pass through formula optimization, obtain and be simple and easy to use, the sputum treatment solution of safety non-toxic, and by utilizing treatment solution to carry out inactivation treatment to cause of disease in sample phase, improve biological safety, simultaneously by the method for osmotic pressure, human body cast-off cells in cracking sputum, reduce the interference of background.
The present invention is easy to use, and sputum treatment solution normal temperature uses, normal temperature transport is preserved.
The present invention is with low cost, preparation is simple, to auxiliary appliance without particular requirement, does not need to carry out loaded down with trivial details training to user, is applicable to extensive tuberculosis Screening Diagnosis.
Claims (6)
1., for the sputum treatment solution that tubercule bacillus detects, it is characterized in that it is made up of following composition and part by weight: ethanol 5-20%, Virahol 10-25%, boric acid 0.2-1.5%, EDETATE SODIUM 0.01-0.2%, SDS0.001-0.1%, mucolytic agent 3-12%, distilled water 40-75%.
2. sputum treatment solution according to claim 1, is characterized in that not needing concuss in sputum treating processes or rocking, and only needs to mix gently and can melt sputum.
3. sputum treatment solution according to claim 1, is characterized in that, in the process sampled, cause of disease contained in sputum comprises tubercule bacillus and was namely inactivated within 1 minute, avoids infected possibility in operator's subsequent processes.
4. sputum treatment solution according to claim 1, the amount of process sputum improves a lot, and maximum ratio can reach 2.5:1(sputum treatment solution: sputum).
5. sputum treatment solution according to claim 1, it is characterized in that sputum treatment solution can thoroughly liquefy sputum, cracking human body cast-off cells, release tubercule bacillus, in conjunction with simple centrifugally operated, get final product enrichment of bacterial, reach and put forward highly sensitive object, simultaneously for the cracking of human body cast-off cells, achieve the object reducing cellular context.
6. sputum process according to claim 1, can use at 4-70 DEG C and operate, also can transport at-10-40 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510784562.4A CN105274185A (en) | 2015-11-16 | 2015-11-16 | Sputum treating liquid for detecting Mycobacterium tuberculosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510784562.4A CN105274185A (en) | 2015-11-16 | 2015-11-16 | Sputum treating liquid for detecting Mycobacterium tuberculosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105274185A true CN105274185A (en) | 2016-01-27 |
Family
ID=55144013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510784562.4A Pending CN105274185A (en) | 2015-11-16 | 2015-11-16 | Sputum treating liquid for detecting Mycobacterium tuberculosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105274185A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106967778A (en) * | 2017-03-27 | 2017-07-21 | 南京邦博生物技术有限公司 | A kind of quick sputum dissolving preserves liquid |
| CN107400695A (en) * | 2017-03-06 | 2017-11-28 | 李齐 | A kind of sputum microorganism sample homogeneity reagent |
| CN112574938A (en) * | 2019-09-29 | 2021-03-30 | 广东体必康生物科技有限公司 | Sputum treatment fluid for membrane filtration enriched bacteria and application thereof |
| CN117486402A (en) * | 2023-11-02 | 2024-02-02 | 贵州省人民医院 | Sputum treatment method for medical examination |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1816634A (en) * | 2003-07-11 | 2006-08-09 | Cytyc公司 | Detection of targets in preserved solutions |
| WO2010088191A1 (en) * | 2009-01-27 | 2010-08-05 | Teleflex Medical Incorporated | Sputum dissolving suctioning solution for endotracheal and tracheostomy tubes |
| CN102226160A (en) * | 2011-05-13 | 2011-10-26 | 广州金域医学检验中心有限公司 | Legionella isolate culture sputum digestive fluid |
| CN102258003A (en) * | 2010-05-28 | 2011-11-30 | 孝感市中心医院 | Liquid based cell preserving fluid |
| CN102318597A (en) * | 2011-08-19 | 2012-01-18 | 张雪云 | Liquid-based cell preservation liquid composite and preparation method thereof |
| CN104561230A (en) * | 2015-01-22 | 2015-04-29 | 四川金域医学检验中心有限公司 | Sputum specimen homogenization method and preparation of reagent for medical detection of sputum specimen |
-
2015
- 2015-11-16 CN CN201510784562.4A patent/CN105274185A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1816634A (en) * | 2003-07-11 | 2006-08-09 | Cytyc公司 | Detection of targets in preserved solutions |
| WO2010088191A1 (en) * | 2009-01-27 | 2010-08-05 | Teleflex Medical Incorporated | Sputum dissolving suctioning solution for endotracheal and tracheostomy tubes |
| CN102258003A (en) * | 2010-05-28 | 2011-11-30 | 孝感市中心医院 | Liquid based cell preserving fluid |
| CN102226160A (en) * | 2011-05-13 | 2011-10-26 | 广州金域医学检验中心有限公司 | Legionella isolate culture sputum digestive fluid |
| CN102318597A (en) * | 2011-08-19 | 2012-01-18 | 张雪云 | Liquid-based cell preservation liquid composite and preparation method thereof |
| CN104561230A (en) * | 2015-01-22 | 2015-04-29 | 四川金域医学检验中心有限公司 | Sputum specimen homogenization method and preparation of reagent for medical detection of sputum specimen |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107400695A (en) * | 2017-03-06 | 2017-11-28 | 李齐 | A kind of sputum microorganism sample homogeneity reagent |
| CN107400695B (en) * | 2017-03-06 | 2018-03-06 | 李齐 | A kind of sputum sample homogeneity method and the reagent used |
| CN106967778A (en) * | 2017-03-27 | 2017-07-21 | 南京邦博生物技术有限公司 | A kind of quick sputum dissolving preserves liquid |
| CN106967778B (en) * | 2017-03-27 | 2018-04-06 | 南京邦博生物技术有限公司 | A kind of quick sputum dissolving preserves liquid |
| CN112574938A (en) * | 2019-09-29 | 2021-03-30 | 广东体必康生物科技有限公司 | Sputum treatment fluid for membrane filtration enriched bacteria and application thereof |
| CN117486402A (en) * | 2023-11-02 | 2024-02-02 | 贵州省人民医院 | Sputum treatment method for medical examination |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8338128B2 (en) | Microbial detection and quantification | |
| Zuerner | Laboratory maintenance of pathogenic Leptospira | |
| Nolte et al. | Influenza A virus infection complicated by fatal myocarditis | |
| WO2008079463A2 (en) | Biological organism identification product and methods | |
| TWI577442B (en) | The method of removing bacterial endotoxin from biological products and the preparation of its biological products method | |
| CN105274185A (en) | Sputum treating liquid for detecting Mycobacterium tuberculosis | |
| Nickerson et al. | Bile salt-induced biofilm formation in enteric pathogens: techniques for identification and quantification | |
| Thomason et al. | STAINING BACTERIAL SMEARS WITH FLUORESCENT ANTIBODY II: Rapid Detection of Varying Numbers of Malleomyces pseudomallei in Contaminated Materials and Infected Animals | |
| CN104483409A (en) | Staphylococcus aureus identification method based on fingerprint | |
| CN105784999A (en) | Method and kit for immunological detection of mycobacterium tuberculosis complex | |
| CN102703609B (en) | Onsite quick detection kit of channel catfish virus and detection method thereof | |
| CN102146430B (en) | Mycobacterium tuberculosis medicament sensitive phenotype detection method and application of method | |
| Smith | ELECTRON AND LIGHT MICROSCOPIC STUDIES OF BACTERIAL NUCLEI II: An Improved Staining Technique for the Nuclear Chromatin of Bacterial Cells | |
| CN101875980A (en) | A kit and detection method for detecting Macrobrachium rosenbergii Nodavirus | |
| CN111876330A (en) | A virus delivery medium suitable for nucleic acid detection and preparation method thereof | |
| Hanlon | Fundamentals of microbiology | |
| CN102818891A (en) | Rabbit Klebsiella pneumoniae agglutinogen and application of rabbit Klebsiella pneumoniae agglutinogen | |
| CN101693887A (en) | Fast cultivation and identification method of high throughput virus and applications thereof | |
| JP4876251B2 (en) | Method for determining the presence ratio of live bacteria, dead bacteria and pseudo-viable bacteria | |
| EA036766B1 (en) | Pathogen detection method | |
| CN106755271B (en) | A kind of leptospira rapid dyeing reagent and preparation method and application | |
| CN118937028A (en) | A kind of acid-fast bacillus positive liquid control and its preparation method and application | |
| CN103698513A (en) | Rapid detection method for coleus blumei viroids | |
| CN115541881B (en) | A detection kit capable of inactivating novel coronavirus antigen reagents | |
| Rawat et al. | Comparison and evaluation of rapid cold AFB stain with Ziehl-Neelsen staining in a prospective study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160127 |